BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB clinical trials

Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)

This study is looking at a new treatment combination — rituximab, bendamustine, cytarabine, and venetoclax (V-RBAC) — for older patients with a specific type of blood cancer called mantle cell lymphoma. It aims to see how well this new treatment stops the cancer from growing for at least two years.